Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

BACKGROUND: Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. METHODS: This was a multisite single arm phase II trial of buparlisib 100 mg ± enza...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Cancer
Glavni autori: Armstrong, Andrew J., Halabi, Susan, Healy, Patrick, Alumkal, Joshi J., Winters, Carolyn, Kephart, Julie, Bitting, Rhonda L., Hobbs, Carey, Soleau, Colleen F., Beer, Tomasz M., Slottke, Rachel, Mundy, Kelly, Yu, Evan Y., George, Daniel J.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6345641/
https://ncbi.nlm.nih.gov/pubmed/28502694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2017.02.030
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items